NCT04130516
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentLinnaeus Therapeutics, Inc.
~200 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:LNS8801 -Small molecule, orally bioavailable, selective agonist of GPERPembrolizumab - anti-PD-1 antibody
At a glance
Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events observed for LNS8801 dosed alone and in combination with pembrolizumab
Measured over Duration of study, approximately 24 months
Conditions
Where it's being run
10 sites across 7 statesNew York2
Pennsylvania2
Texas2
California1
Connecticut1
Massachusetts1
New Mexico1
Study leadership
- Tina Garyantes, PhD · STUDY_DIRECTOR · Linnaeus Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Note: Patients in an LNS8801/pembrolizumab combination cohort must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of acute graft versus host disease \[GVHD\]) 5. Patients must not be participating in another study of an investigational agent or have used an investigational device within 4 weeks before the first dose of study drug.
What this trial measures
- Adverse events observed for LNS8801 dosed alone and in combination with pembrolizumabDuration of study, approximately 24 months